Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

At Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz in Madrid, Spain, the Oncology research program focuses on neoplasms and related skin and connective tissue diseases. The studies are centered on understanding disease behavior, assessing new treatment options, and improving care for people with difficult-to-treat cancers and inflammatory skin conditions.

• Research in recurrent and platinum-resistant ovarian cancer, including fallopian tube and primary peritoneal carcinoma
• Trials in endometrial cancer and recurrent cervical cancer aimed at testing new cancer therapies
• Evaluation of novel treatments for advanced gynecologic cancers with a focus on safety and effectiveness

With 15 clinical trials and 245 investigators contributing to the work, the site is actively exploring new approaches for women’s cancers, including studies designed to improve treatment response in recurrent disease.

The site also conducts clinical research in skin and connective tissue diseases, with a strong emphasis on atopic dermatitis. These trials are evaluating whether newer therapies can better reduce symptoms, improve skin severity, and support longer-lasting disease control for adults and adolescents living with moderate-to-severe disease.

• Studies in atopic dermatitis focused on improving signs, symptoms, and overall disease severity
• Assessment of emerging treatments intended to maintain clinical benefit over time
• Research aimed at improving quality of life for patients with chronic inflammatory skin disease

This work reflects a broader effort at Hospital Universitario La Paz to test innovative therapies across both inflammatory and cancer-related conditions.

A notable part of the research portfolio involves testing new anticancer therapies for hard-to-treat gynecologic malignancies. The studies are designed to evaluate whether investigational treatments can offer meaningful benefit for patients whose cancers have returned or no longer respond well to standard care.

• First-in-human studies assessing the safety of new cancer treatments
• Trials in ARID1a-mutated ovarian, fallopian tube, and primary peritoneal carcinoma
• Research in recurrent endometrial and recurrent epithelial ovarian cancer

These studies combine drug development and treatment effectiveness research, helping define whether promising new options can move closer to routine use in oncology care.